CRISPR Therapeutics AG logo

CRISPR Therapeutics AGNASDAQ: CRSP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Switzerland

IPO:

19 October 2016

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.34 B
-41%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector
-42%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:55:04 GMT
$50.99+$4.19(+8.95%)

Dividend

No data over the past 3 years
$31.88 M$6.81 M

Analysts recommendations

Institutional Ownership

CRSP Latest News

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
fool.com02 November 2024 Sentiment: NEUTRAL

It won't be able to be profitable without hitting its targets for both of these figures.

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
zacks.com28 October 2024 Sentiment: POSITIVE

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

Crispr Therapeutics: Poised For A Major Turnaround
seekingalpha.com28 October 2024 Sentiment: POSITIVE

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline.

The Ultimate Biotech Stock to Buy With $50 Right Now
fool.com26 October 2024 Sentiment: POSITIVE

This company might be worth far more than many realize.

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
zacks.com25 October 2024 Sentiment: NEGATIVE

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.36, representing a -1.23% change from its previous close.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
zacks.com21 October 2024 Sentiment: NEGATIVE

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
zacks.com21 October 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 67.5% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
zacks.com15 October 2024 Sentiment: POSITIVE

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

Is CRISPR Therapeutics Stock a Buy?
fool.com13 October 2024 Sentiment: POSITIVE

The markets this biotech is looking to enter could be extremely lucrative.

2 Biotech Stocks That Are Screaming Buys This Month
fool.com12 October 2024 Sentiment: POSITIVE

They won't remain southbound forever.

What type of business is CRISPR Therapeutics AG?

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

What sector is CRISPR Therapeutics AG in?

CRISPR Therapeutics AG is in the Healthcare sector

What industry is CRISPR Therapeutics AG in?

CRISPR Therapeutics AG is in the Biotechnology industry

What country is CRISPR Therapeutics AG from?

CRISPR Therapeutics AG is headquartered in Switzerland

When did CRISPR Therapeutics AG go public?

CRISPR Therapeutics AG initial public offering (IPO) was on 19 October 2016

What is CRISPR Therapeutics AG website?

https://www.crisprtx.com

Is CRISPR Therapeutics AG in the S&P 500?

No, CRISPR Therapeutics AG is not included in the S&P 500 index

Is CRISPR Therapeutics AG in the NASDAQ 100?

No, CRISPR Therapeutics AG is not included in the NASDAQ 100 index

Is CRISPR Therapeutics AG in the Dow Jones?

No, CRISPR Therapeutics AG is not included in the Dow Jones index

When was CRISPR Therapeutics AG the previous earnings report?

No data

When does CRISPR Therapeutics AG earnings report?

The next expected earnings date for CRISPR Therapeutics AG is 06 November 2024